Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Antiepileptic drugs' tolerability and safety--a systematic review and meta-analysis of adverse effects in dogs.

Charalambous M, Shivapour SK, Brodbelt DC, Volk HA.

BMC Vet Res. 2016 May 21;12:79. doi: 10.1186/s12917-016-0703-y. Review.

2.

Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews.

Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham JJ.

BMJ. 2014 Nov 21;349:g6501. doi: 10.1136/bmj.g6501.

3.

Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources.

Loke YK, Golder SP, Vandenbroucke JP.

Ther Adv Drug Saf. 2011 Apr;2(2):59-68. doi: 10.1177/2042098611401129. Review.

4.

Quality of reporting in systematic reviews of adverse events: systematic review.

Zorzela L, Golder S, Liu Y, Pilkington K, Hartling L, Joffe A, Loke Y, Vohra S.

BMJ. 2014 Jan 8;348:f7668. doi: 10.1136/bmj.f7668. Review.

5.

Quantification of harms in cancer screening trials: literature review.

Heleno B, Thomsen MF, Rodrigues DS, Jørgensen KJ, Brodersen J.

BMJ. 2013 Sep 16;347:f5334. doi: 10.1136/bmj.f5334. Review.

6.

Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview.

Golder S, Loke YK, Bland M.

PLoS Med. 2011 May;8(5):e1001026. doi: 10.1371/journal.pmed.1001026. Epub 2011 May 3. Review.

7.

Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues.

Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, Ten Haken RK, Yorke ED.

Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S3-9. doi: 10.1016/j.ijrobp.2009.09.040.

8.

Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses.

Ioannidis JP.

CMAJ. 2009 Oct 13;181(8):488-93. doi: 10.1503/cmaj.081086. Epub 2009 Aug 4. Review. No abstract available.

9.

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D.

BMJ. 2009 Jul 21;339:b2700. doi: 10.1136/bmj.b2700.

10.

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D.

PLoS Med. 2009 Jul 21;6(7):e1000100. doi: 10.1371/journal.pmed.1000100. Epub 2009 Jul 21.

11.

Search strategies to identify information on adverse effects: a systematic review.

Golder S, Loke Y.

J Med Libr Assoc. 2009 Apr;97(2):84-92. doi: 10.3163/1536-5050.97.2.004. Review.

12.

Improving the use of research evidence in guideline development: 7. Deciding what evidence to include.

Oxman AD, Schünemann HJ, Fretheim A.

Health Res Policy Syst. 2006 Dec 1;4:19.

13.

Peer-reviewed publication of clinical trials completed for pediatric exclusivity.

Benjamin DK Jr, Smith PB, Murphy MD, Roberts R, Mathis L, Avant D, Califf RM, Li JS.

JAMA. 2006 Sep 13;296(10):1266-73.

15.

Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies.

Papanikolaou PN, Christidi GD, Ioannidis JP.

CMAJ. 2006 Feb 28;174(5):635-41.

Supplemental Content

Support Center